公开(公告)号：US20100215667A1

公开(公告)日：2010-08-26

申请号：US12723440

申请日：2010-03-12

Applicant: Joy M. Campbell ,  Ronald E. Strohbehn ,  Eric M. Weaver ,  Barton S. Borg ,  Louis E. Russell ,  Francisco Javier Polo Pozo ,  John D. Arthington ,  James D. Quigley, III

Inventor： Joy M. Campbell ,  Ronald E. Strohbehn ,  Eric M. Weaver ,  Barton S. Borg ,  Louis E. Russell ,  Francisco Javier Polo Pozo ,  John D. Arthington ,  James D. Quigley, III

IPC: A61K39/42 ,  A61K39/395 ,  A61P19/02 ,  A61P3/10 ,  A61P27/02 ,  A61P11/06 ,  A61P7/00 ,  A61P25/00

CPC classification number: A61K39/15 ,  A23K10/00 ,  A61K35/16 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/505 ,  A61K2039/542 ,  A61K2039/552 ,  C07K16/02 ,  C07K16/04 ,  C07K16/06 ,  C07K16/065 ,  C12N2720/12334 ,  C12N2770/10011 ,  C12N2770/10034

Abstract: Methods and compositions are disclosed for the dietary modulation of the immune system and gut microbial response in animals. Applicant has identified that oral administration of a supplemental spray dried plasma purified from animal serum can modulate serum IgG levels for treatment in such things as diminished immune capacity, intestinal microbial balance, autoimmune disorders, potentiation of vaccination protocols, and improvement of overall health and weight gain in animals, including humans.

Abstract translation: 公开了用于免疫系统的饮食调节和动物肠内微生物反应的方法和组合物。 申请人已经确定，从动物血清中纯化的补充喷雾干燥血浆的口服给药可以调节血清IgG水平以进行治疗，例如免疫能力降低，肠微生物平衡，自身免疫疾病，增强疫苗接种方案以及提高整体健康和体重 在动物，包括人类的增益。

公开(公告)号：US20100068227A1

公开(公告)日：2010-03-18

申请号：US12227250

申请日：2007-05-11

Applicant: Krishna Murthy Ella ,  Victor Jerusha Augustus Harshavardhan Gutla ,  Krishna Mohan Vadrevu ,  Smita Suneel Singhania

Inventor： Krishna Murthy Ella ,  Victor Jerusha Augustus Harshavardhan Gutla ,  Krishna Mohan Vadrevu ,  Smita Suneel Singhania

IPC: A61K39/15 ,  A61K39/12 ,  A61P31/12 ,  A61P37/04 ,  A61P31/14

CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/545 ,  A61K2039/55505 ,  C12N7/00 ,  C12N2720/12334

Abstract: The present invention relates to a composition comprising a viral antigen, a first protein and a second protein. Optionally, the composition also comprises three different disaccharaides, or, optionally, the composition comprises a primary sugar and at least one, preferably two secondary sugars. The present invention also relates to the use of a viral antigen, a first protein and a second protein for the manufacture of a composition, preferably a vaccine. The present invention furthermore relates to a method of treatment or prevention of virus associates diseases in humans. Moreover, the present invention relates to a method of adapting a virus to a suitable cell-line. The invention is also useful for the production of virus suspensions suitable for making stable, live/inactivated, monovalent and/or polyvalent, liquid/lyophilized rotavirus vaccine compositions for oral and/or nasal or any other suitable route of administration in human.

Abstract translation: 本发明涉及包含病毒抗原，第一蛋白质和第二蛋白质的组合物。 任选地，组合物还包含三种不同的糖苷，或者任选地，组合物包含初级糖和至少一种，优选两种二级糖。 本发明还涉及病毒抗原，第一蛋白质和第二蛋白质用于制备组合物，优选疫苗的用途。 本发明还涉及治疗或预防人类疾病病毒相关疾病的方法。 此外，本发明涉及使病毒适应于合适的细胞系的方法。 本发明还可用于生产适用于制备用于口服和/或鼻或其它合适的人类给药途径的稳定，活/灭活的单价和/或多价液体/冻干轮状病毒疫苗组合物的病毒悬浮液。

公开(公告)号：US20100047278A1

公开(公告)日：2010-02-25

申请号：US12443071

申请日：2007-09-28

Applicant: Wonyong Kim ,  Inseok Lim ,  Le Van Phan ,  Sun-Woo Nam ,  Jung-Hoon Yoon

Inventor： Wonyong Kim ,  Inseok Lim ,  Le Van Phan ,  Sun-Woo Nam ,  Jung-Hoon Yoon

IPC: A61K39/15 ,  C12N7/00 ,  C07K16/08 ,  C12Q1/70

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K2039/5252 ,  C07K16/10 ,  C12N2720/12321 ,  C12N2720/12334

Abstract: Provided are G12 human rotaviruses having VP7 gene of SEQ ID NO: 1 or 2 and VP4 gene of SEQ ID NO: 3 or 4; antibodies specific for said rotaviruses; and a vaccine composition containing the same. The antibodies and the vaccine composition are effective for diagnosing rotavirus infection and for treatment of diseases caused by rotavirus.

Abstract translation: 提供具有SEQ ID NO：1或2的VP7基因和SEQ ID NO：3或4的VP4基因的G12人轮状病毒; 对所述轮状病毒特异的抗体; 和含有该组合物的疫苗组合物。 抗体和疫苗组合物可有效诊断轮状病毒感染和治疗由轮状病毒引起的疾病。

公开(公告)号：US20090130145A1

公开(公告)日：2009-05-21

申请号：US11843256

申请日：2007-08-22

Applicant: Brigitte Desiree Alberte Colau ,  Francoise Denamur ,  Isabelle Knott ,  Annick Poliszczak ,  Georges Thiry ,  Vincent Vande Velde

Inventor： Brigitte Desiree Alberte Colau ,  Francoise Denamur ,  Isabelle Knott ,  Annick Poliszczak ,  Georges Thiry ,  Vincent Vande Velde

IPC: A61K39/15 ,  C12N7/00

CPC classification number: A61K39/15 ,  A61K8/0216 ,  A61K9/0056 ,  A61K9/0095 ,  A61K9/19 ,  A61K9/2095 ,  A61K39/12 ,  A61K39/39 ,  A61K47/02 ,  A61K47/183 ,  A61K47/26 ,  A61K47/36 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/55505 ,  C07K14/005 ,  C12N7/00 ,  C12N2720/12321 ,  C12N2720/12322 ,  C12N2720/12332 ,  C12N2720/12334 ,  C12N2720/12351 ,  Y02A50/466

Abstract: The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue.

Abstract translation: 本发明提供了包含单个变体或基本上单个变体的减毒轮状病毒群，其由编码指定为VP4和VP7的主要病毒蛋白质中的至少一种的核苷酸序列限定。 本发明特别提供了称为P43的轮状病毒群体。 本发明进一步提供了一种轮状病毒疫苗的新型制剂，其是当放置在舌头上时立即溶解的快速溶解片剂形式。

公开(公告)号：US20090028828A1

公开(公告)日：2009-01-29

申请号：US12063602

申请日：2006-08-15

Applicant: Brigitte Desiree Alberte Colau ,  Beatrice Arsene Virginie De Vos

Inventor： Brigitte Desiree Alberte Colau ,  Beatrice Arsene Virginie De Vos

IPC: A61K35/76 ,  A61P1/00

CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K2039/522 ,  A61K2039/5254 ,  A61K2039/542 ,  A61K2039/545 ,  A61K2039/55505 ,  C12N2720/12334

Abstract: The invention provides a method of inducing an immune response against rotavirus strain, the method comprising administering to a subject a composition comprising an attenuated rotavirus strain of a GxPy type, said composition generating an immune response against a rotavirus strain which is neither a Gx nor a Py type.

Abstract translation: 本发明提供了诱导针对轮状病毒株的免疫应答的方法，所述方法包括对受试者施用包含GxPy型减毒轮状病毒株的组合物，所述组合物产生针对轮状病毒株的免疫应答，所述轮状病毒株既不是Gx也不是 Py型。

公开(公告)号：US07037712B2

公开(公告)日：2006-05-02

申请号：US09464767

申请日：1999-12-16

Applicant: Gerald Wayne Both ,  David Bernard Boyle ,  Sadhanshu Vrati

Inventor： Gerald Wayne Both ,  David Bernard Boyle ,  Sadhanshu Vrati

IPC: C12N15/861 ,  C07H21/04 ,  A61K35/76 ,  A61K48/00

CPC classification number: C12N15/86 ,  C07K14/005 ,  C07K14/43554 ,  C07K14/43577 ,  C12N2710/10122 ,  C12N2710/10143 ,  C12N2720/12334

Abstract: A genome of an ovine adenovirus designated OAV287 is isolated from sheep and sequenced. Portions of the genome not essential for maintenance or viability of the virus can be deleted or altered. A nucleotide sequence encoding a non-adenoviral polypeptide can be incorporated into the genome. The a full-length clone of the genome can be provided as part of a plasmid or viral vector. Cells can be transformed with a vector of the invention such that they express an exogenous protein.

Abstract translation: 从绵羊中分离出称为OAV287的羊腺病毒基因组，并进行测序。 可能会删除或改变对病毒的维护或生存能力不重要的基因组部分。 可以将编码非腺病毒多肽的核苷酸序列并入基因组。 基因组的全长克隆可以作为质粒或病毒载体的一部分提供。 可以用本发明的载体转化细胞，使得它们表达外源蛋白质。

公开(公告)号：US20040202660A1

公开(公告)日：2004-10-14

申请号：US10470981

申请日：2004-05-20

Inventor： Joy Campbell ,  Ronald E. Strohbehn ,  Eric M. Weaver ,  Barton S. Borg ,  Louis E. Russell ,  Francisco Javier Polo Pozo ,  John D. Arthington ,  James D. Quiglev

IPC: A61K039/395 ,  A61K035/78

CPC classification number: A61K39/395 ,  A61K35/16 ,  A61K35/20 ,  A61K39/12 ,  A61K39/15 ,  A61K39/39 ,  A61K2039/505 ,  A61K2039/542 ,  C07K16/02 ,  C07K16/04 ,  C07K16/06 ,  C07K16/065 ,  C07K2317/77 ,  C12N2720/12334 ,  C12N2770/10034

Abstract: Methods and compositions are disclosed for modulating the immune system of animals. Applicant has identified that oral administration of immunoglobulin or plasma fractions purified from animal serum can modulate serum IgG and/or TNF-null levels for treatment of autoimmune disorders, potentiation of vaccination protocols, and improvement of overall health and weight gain in animals, including humans.

Abstract translation: 公开了调节动物免疫系统的方法和组合物。 申请人已经确定，从动物血清中纯化的免疫球蛋白或血浆级分的口服给药可以调节血清IgG和/或TNF-Delta水平以治疗自身免疫性疾病，增强疫苗接种方案，以及提高包括人在内的动物的整体健康和体重增加 。

公开(公告)号：US20040043032A1

公开(公告)日：2004-03-04

申请号：US10297256

申请日：2003-05-12

Inventor： lan Farquhar Campbell McKenzie ,  Geoffrey Allan Pietersz ,  Christina Cheers ,  John Stambas

IPC: A61K039/00 ,  A61K039/38

CPC classification number: A61K31/715 ,  A61K39/0208 ,  A61K39/04 ,  A61K39/12 ,  A61K39/15 ,  A61K39/385 ,  A61K39/39 ,  A61K2039/541 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55544 ,  A61K2039/55566 ,  A61K2039/55583 ,  A61K2039/57 ,  A61K2039/6087 ,  C12N2710/20034 ,  C12N2720/12334 ,  Y02A50/412

Abstract: The present invention provides a method of immunising a subject comprising the step of administering a composition comprising an antigen and a carbohydrate polymer comprising mannose to a mucosal site of the subject, methods of use of the composition for vaccination and sterilization and use of the composition in manufacturing a medicament.

Abstract translation: 本发明提供免疫受试者的方法，包括以下步骤：将包含抗原和包含甘露糖的碳水化合物聚合物的组合物施用于受试者的粘膜部位，使用该组合物进行疫苗接种和灭菌的方法以及使用该组合物 制造药物。

公开(公告)号：US06616931B1

公开(公告)日：2003-09-09

申请号：US09631807

申请日：2000-08-03

Applicant: Carl J. Burke ,  David B. Volkin

Inventor： Carl J. Burke ,  David B. Volkin

IPC: A61K3915

CPC classification number: A61K39/15 ,  A61K39/12 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/42 ,  A61K2039/542 ,  C12N2720/12334

Abstract: The present invention provides liquid and lyophilized formulations of vaccines against rotavirus infection and methods of their preparation. The formulations include buffering agents appropriate for oral administration of rotavirus vaccines. The formulations also include compounds to stabilize of the vaccine compositions against loss of potency.

Abstract translation: 本发明提供了针对轮状病毒感染的疫苗的液体和冻干制剂及其制备方法。 制剂包括适合于轮状病毒疫苗口服给药的缓冲剂。 制剂还包括稳定疫苗组合物以抵抗效力丧失的化合物。

公开(公告)号：US20030113788A1

公开(公告)日：2003-06-19

申请号：US10328475

申请日：2002-12-24

Applicant: Baylor College of Medicine

Inventor： Mary K. Estes

IPC: C12Q001/70 ,  A61K039/15 ,  C12Q001/68 ,  C12N005/06 ,  C12N005/16

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/145 ,  A61K39/15 ,  A61K39/39 ,  A61K2039/5252 ,  A61K2039/5258 ,  A61K2039/541 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55588 ,  C07K2319/00 ,  C12N2720/12322 ,  C12N2720/12334 ,  C12N2760/16134 ,  Y02A50/412

Abstract: This invention relates to a method of potentiating an immune response by administering a viral enterotoxin or derivative as an adjuvant. More particularly it relates to administering a viral enterotoxin or derivative as an adjuvant and an antigen to a mucosal surface of a mammal.

Abstract translation: 本发明涉及通过施用病毒肠毒素或其衍生物作为佐剂来增强免疫应答的方法。 更具体地说，涉及向哺乳动物的粘膜表面施用病毒肠毒素或其衍生物作为佐剂和抗原。